Seer Inc（SEER）股票分析SEERSeer Inc

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument. It operates in the Technology sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Seer Inc is currently priced at $1.97, which is significantly lower than the analyst target of $4, indicating potential for growth. However, the stock has a low RSI of 31.052, suggesting it is oversold, but the negative earnings trend with a forward P/E of 0 and a net income loss of -16,837,000 USD in Q1 2026 raises concerns about its immediate financial health. Therefore, while there is potential upside, the ongoing losses and market volatility suggest a cautious approach is warranted.